We are excited to share the news that Genoox, an UpWest-backed company, has raised $6M to continue scaling in the US market.
Genoox has developed a first-of-its-kind cloud-based platform for genomic data. By automating data interpretation and providing millions of in-house and public data points through a proprietary search engine, Genoox improves patient outcomes with increased accuracy and efficiency, making personalized medicine a reality.
CEO Amir Trabelsi said, “We want to bring [medical institutions] the ability to run clinical applications and use genomic data part of the clinical routine.” He continued, “Genomic data is complicated especially when it comes to clinical outcomes — how can you make things more actionable for [professionals], how can you reduce the cost and overhead, and how can you filter out what is relevant and not relevant.”
The round was led by Triventures, with participation from prior investors Inimiti Capital and Glilot Capital Partners. As part of the new financing, Triventures partner Dr. Peter Fitzgerald will join the Genoox board. He said, “We invested in Genoox because the company is led by a superb, multidisciplinary team that has developed a robust and scalable platform differentiated by its accurate, clinical genomic analysis and treatment recommendations.”
You can read the official press release here, and see Genoox featured in TechCrunch here.
UpWest was Genoox’s first investor in 2014, when the team was just the two co-founders Amir Trabelsi and Moshe Einhorn. The team has since grown to have offices in Tel Aviv, New York, and Palo Alto. We couldn’t be happier for Genoox, and are excited to continue to watch them grow.